[go: up one dir, main page]

UY34300A - COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit - Google Patents

COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit

Info

Publication number
UY34300A
UY34300A UY0001034300A UY34300A UY34300A UY 34300 A UY34300 A UY 34300A UY 0001034300 A UY0001034300 A UY 0001034300A UY 34300 A UY34300 A UY 34300A UY 34300 A UY34300 A UY 34300A
Authority
UY
Uruguay
Prior art keywords
kinase
inhibitors
kit
compositions
compounds
Prior art date
Application number
UY0001034300A
Other languages
English (en)
Inventor
Molteni Valentina
Yeh Vince
Li Xiaolin
Liu Xiaodong
Jon Christopher Loren
Nabakka Juliet
Nguyen Bao
Hank Michael James Petrassi
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of UY34300A publication Critical patent/UY34300A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La invención proporciona compuestos y composiciones farmacéuticas de los mismos, los cuales son útiles como inhibidores de las proteinas quinasas, así como también métodos para utilizar tales compuestos y así tratar, alivar o prevenir una condición asociada con actividad anormal o desregulada de las quinasas. En algunas realizaciones, la invención proporciona métodos para utilizar tales compuestos para tratar, aliviar o prevenir enfermedades o trastornos que involucran activación anormal de la c- kit o quinasas c- kit y PDGFR (PDGFRa, PDGFRß).
UY0001034300A 2011-09-01 2012-08-29 COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit UY34300A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161530028P 2011-09-01 2011-09-01

Publications (1)

Publication Number Publication Date
UY34300A true UY34300A (es) 2013-04-05

Family

ID=46829898

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034300A UY34300A (es) 2011-09-01 2012-08-29 COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit

Country Status (41)

Country Link
US (1) US9199981B2 (es)
EP (1) EP2751102B1 (es)
JP (1) JP6117208B2 (es)
KR (1) KR101959590B1 (es)
CN (1) CN103764653B (es)
AP (1) AP2014007494A0 (es)
AR (1) AR087752A1 (es)
AU (1) AU2012300248B2 (es)
BR (1) BR112014004504B1 (es)
CA (1) CA2845159C (es)
CL (1) CL2014000494A1 (es)
CO (1) CO6900140A2 (es)
CR (1) CR20140106A (es)
CU (1) CU20140023A7 (es)
CY (1) CY1121695T1 (es)
DK (1) DK2751102T3 (es)
EA (1) EA024293B1 (es)
ES (1) ES2732671T3 (es)
GT (1) GT201400036A (es)
HR (1) HRP20191140T1 (es)
HU (1) HUE044373T2 (es)
IL (1) IL231226A (es)
JO (1) JOP20120246B1 (es)
LT (1) LT2751102T (es)
MA (1) MA35459B1 (es)
ME (1) ME03395B (es)
MX (1) MX342329B (es)
MY (1) MY167245A (es)
PE (1) PE20141033A1 (es)
PL (1) PL2751102T3 (es)
PT (1) PT2751102T (es)
RS (1) RS59025B1 (es)
SG (1) SG2014011050A (es)
SI (1) SI2751102T1 (es)
TN (1) TN2014000061A1 (es)
TR (1) TR201909189T4 (es)
TW (1) TWI543981B (es)
UA (1) UA110841C2 (es)
UY (1) UY34300A (es)
WO (1) WO2013033070A1 (es)
ZA (1) ZA201401113B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012302042B2 (en) 2011-09-01 2016-03-31 Novartis Ag Compounds and compositions as c-kit kinase inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
JP6259823B2 (ja) * 2012-07-13 2018-01-10 ユーシービー バイオファルマ エスピーアールエル Tnf活性の調節物質としてのイミダゾピリジン誘導体
WO2014110200A1 (en) 2013-01-10 2014-07-17 Zisman Lawrence S Non-selective kinase inhibitors
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
JP6483714B2 (ja) 2013-10-11 2019-03-13 ローレンス エス. ジスマン, 噴霧乾燥製剤
CN106414440A (zh) * 2013-12-05 2017-02-15 拜耳制药股份公司 芳基和杂芳基取代的咪唑并[1,2-a]吡啶-3-羧酰胺及其用途
CN103965190A (zh) * 2014-05-20 2014-08-06 定陶县友帮化工有限公司 一种咪唑并[1,2-a]吡啶-3-甲酸的合成方法
EA201890204A1 (ru) 2015-07-02 2018-06-29 Янссен Сайенсиз Айрлэнд Юси Антибактериальные соединения
US10059708B2 (en) * 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
EP3472152A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacte rials
KR20190017948A (ko) 2016-06-16 2019-02-20 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항균제로서의 헤테로고리 화합물
MX2019004855A (es) 2016-10-27 2019-09-19 Pulmokine Inc Politerapia para tratar hipertension pulmonar.
EP3589323B1 (en) 2017-03-01 2024-04-03 Janssen Sciences Ireland Unlimited Company Combination therapy for the treatment of tuberculosis
CN111039946A (zh) * 2018-10-15 2020-04-21 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
MA55976A (fr) * 2019-05-13 2022-03-23 Novartis Ag Formes cristallines de n-(5-(5-((1r, 2s)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl) imidazo [1,2-a] pyridine-3-carboxamide
EP4028399B1 (en) 2019-09-13 2024-02-14 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
PH12022552373A1 (en) 2020-03-17 2023-12-18 Sumitomo Pharma Co Ltd Oxadiazole derivative
US11767319B2 (en) * 2020-07-15 2023-09-26 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
JP2023551434A (ja) * 2020-11-19 2023-12-08 サード ハーモニック バイオ, インコーポレイテッド 選択的c-kitキナーゼ阻害剤の医薬組成物ならびにその作製および使用のための方法
WO2022106615A1 (en) 2020-11-19 2022-05-27 Novartis Ag Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
WO2022182982A1 (en) * 2021-02-26 2022-09-01 Third Harmonic Bio, Inc. Methods for treating c-kit kinase mediated diseases and disorders using a selective c-kit kinase inhibitor
BR112023018662A2 (pt) 2021-03-16 2023-12-19 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
KR20230157445A (ko) 2021-03-17 2023-11-16 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항박테리아성 화합물
AU2022240967A1 (en) 2021-03-17 2023-11-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CA3234515A1 (en) 2021-10-28 2023-05-04 Jose Manuel Bartolome-Nebreda Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2024123966A1 (en) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
TW202430139A (zh) * 2022-12-07 2024-08-01 美商第三諧波生物公司 作為c-Kit激酶抑制劑之化合物及組成物
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518993D0 (en) * 1995-09-16 1995-11-15 Agrevo Uk Ltd Fungicides
US20070072861A1 (en) * 2000-03-27 2007-03-29 Barbara Roniker Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003251561A1 (en) 2002-06-20 2004-01-06 Beacon Looms, Inc. Knitted electrical conductor fabric
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
EP2079729A1 (en) 2006-11-03 2009-07-22 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2012067965A1 (en) * 2010-11-15 2012-05-24 Abbott Laboratories Nampt and rock inhibitors
CN104024254A (zh) * 2011-09-01 2014-09-03 Irm责任有限公司 作为c-Kit激酶抑制剂的化合物和组合物
CA2845791A1 (en) * 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
AU2012302042B2 (en) * 2011-09-01 2016-03-31 Novartis Ag Compounds and compositions as c-kit kinase inhibitors

Also Published As

Publication number Publication date
CN103764653B (zh) 2015-12-02
EA024293B1 (ru) 2016-09-30
CL2014000494A1 (es) 2014-09-05
SG2014011050A (en) 2014-08-28
SI2751102T1 (sl) 2019-08-30
CU20140023A7 (es) 2014-04-24
TW201313716A (zh) 2013-04-01
NZ621092A (en) 2016-06-24
TWI543981B (zh) 2016-08-01
EP2751102B1 (en) 2019-03-27
GT201400036A (es) 2015-06-02
MA35459B1 (fr) 2014-09-01
DK2751102T3 (da) 2019-07-01
HUE044373T2 (hu) 2019-10-28
KR101959590B1 (ko) 2019-03-18
MX342329B (es) 2016-09-26
JP2014525444A (ja) 2014-09-29
PT2751102T (pt) 2019-07-10
CN103764653A (zh) 2014-04-30
BR112014004504A2 (pt) 2017-03-28
US9199981B2 (en) 2015-12-01
ES2732671T3 (es) 2019-11-25
WO2013033070A1 (en) 2013-03-07
PE20141033A1 (es) 2014-08-30
MY167245A (en) 2018-08-14
HRP20191140T1 (hr) 2019-09-20
JOP20120246B1 (ar) 2022-03-14
LT2751102T (lt) 2019-07-10
PL2751102T3 (pl) 2019-09-30
AU2012300248A1 (en) 2014-04-17
CA2845159C (en) 2020-11-03
CO6900140A2 (es) 2014-03-20
AP2014007494A0 (en) 2014-03-31
TN2014000061A1 (en) 2015-07-01
US20130059846A1 (en) 2013-03-07
CR20140106A (es) 2014-05-02
IL231226A0 (en) 2014-04-30
RS59025B1 (sr) 2019-08-30
TR201909189T4 (tr) 2019-07-22
IL231226A (en) 2017-03-30
EA201490540A1 (ru) 2014-06-30
UA110841C2 (uk) 2016-02-25
JP6117208B2 (ja) 2017-04-19
AR087752A1 (es) 2014-04-16
ZA201401113B (en) 2015-10-28
AU2012300248B2 (en) 2015-08-27
BR112014004504B1 (pt) 2022-03-22
ME03395B (me) 2020-01-20
EP2751102A1 (en) 2014-07-09
CA2845159A1 (en) 2013-03-07
MX2014002482A (es) 2014-11-25
KR20140071382A (ko) 2014-06-11
CY1121695T1 (el) 2020-07-31

Similar Documents

Publication Publication Date Title
UY34300A (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
UY34301A (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY34092A (es) Nuevos compuestos como inhibidores de jak
UY34472A (es) Derivados modificados de 4-fenil-piridina
CR20120635A (es) Compuestos heterocìclicos de nitrògeno ùtiles como inhibidores de pde10
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
UY34045A (es) Derivados de imidazopiridina como inhibidores de pi3k
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
UY34212A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
UY34393A (es) Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia
UA116920C2 (uk) Інгібітори fgfr4
UY33958A (es) Inhibidores de la glucosilceramida sintasa
UY34550A (es) Bencilpirazoles sustituidos
UY34445A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
UY34145A (es) Compuestos inhibidores de metaloenzimas
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34146A (es) Compuestos inhibidores de metaloenzimas
CR20150018A (es) Inhibidores macrocíclicos de virus flaviviridae
UY34523A (es) Derivados de betulina
UY34648A (es) Amidas como inhibidores de pim
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34763A (es) Inhibidores de la agregación plaquetaria
MX352617B (es) Compuestos triciclicos fusionados como inhibidores de cinasa raf.
UY33930A (es) Inhibidores novedosos de quinasas

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20211210